Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LYB001 SARS-CoV-2 Vaccine Immunogenicity and Safety Trial
ChiCTR2100052039Phase 3Not yet recruiting
- Sponsor
- Mittaphab Hospital
- Start
- Oct 2021
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of recombinant sars-cov-2 vaccine (cho cell) lyb001 in coronavirus disease 2019 (COVID-19) (7 arms), sponsored by Mittaphab Hospital. Primary endpoints: Immunogenicity (phase II) and Safety (phase III). Planned start Oct 2021; status: not yet recruiting.
02
Drugs
recombinant sars-cov-2 vaccine (cho cell) lyb001
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2100052039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100052039.